Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.
LOS ANGELES — The U.S. Food and Drug Administration (FDA) approved Tepezza™ for the treatment of Thyroid Eye Disease (TED) on January 21, marking the fourth FDA-approved product containing technologies pioneered at The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), in the last 17 years—and the third in the last five years.
Longtime business development executive to oversee incubator facilities and biotech park planning
LOS ANGELES – The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Keith Bronson Hoffman, PhD to Senior Vice President of Business Development and Technology Transfer.
The Lundquist Institute research offers lessons for communities from California to Australia
LOS ANGELES — An investigator from The Lundquist Institute has demonstrated a way to limit the effects of post-traumatic stress disorder in those affected by wildfires through early intervention and triage using a web-based app, providing valuable insight for medical professionals and first responders dealing with the aftermath of another devastating fire season.
Abstaining from cocaine use can help HIV-positive people with cognition
LOS ANGELES — A new study from The Lundquist Institute shows that cocaine use exacerbates memory loss and other neuropsychological impairments among people with HIV, providing new insight into the effects of cocaine and more information to better treat HIV-positive individuals.
New study from The Lundquist Institute can help stop the spread of superbugs
LOS ANGELES — A new study from The Lundquist Institute shows a reliable, repeatable way to reduce the unnecessary use of antibiotics in emergency departments and urgent care centers. Overusing antibiotics does not help patients, wastes money, and more importantly is accelerating the epidemic of drug-resistant bacteria—or “superbugs.”
Study from The Lundquist Institute finds sub-dissociative doses useful for acute flare-ups
LOS ANGELES — A study from The Lundquist Institute shows that modest doses of ketamine can effectively treat acute exacerbations of chronic pain, providing physicians with another proven option aside from addictive opioids, which have devastated communities and resulted in thousands of early deaths in recent years.
Longtime education executive will oversee media and government relations
LOS ANGELES – The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Jody Spillane to Senior Vice President of Public Affairs.
Chlebowski presented findings at San Antonio Breast Cancer Symposium on Friday
SAN ANTONIO — In a Friday morning presentation at the San Antonio Breast Cancer Symposium, one of the biggest international conferences on breast cancer,
The Lundquist Institute investigator Dr. Rowan Chlebowski shared new data that could help dramatically reduce the risk of breast cancer in postmenopausal women who are on hormone therapy.
Study from The Lundquist Institute shows viable alternative to intravenous treatment
LOS ANGELES — Findings from a study from The Lundquist Institute could reduce a major source of headaches for severe migraine sufferers: hospital visits.
Many people suffering from migraine headaches can control them at home through common oral medications such as sumatriptan, but there’s a substantial population that requires professional treatment to mitigate the unbearable pain. For the last four decades, that treatment has consisted of the insertion of an intravenous line to pump medicine—most commonly prochlorperazine—directly into the patient’s bloodstream.
The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference
Study shows The Lundquist Institute is top-tier venue for pharmaceutical research
PHILADELPHIA — Findings from a new study provide a promising pathway toward reducing the impact of heart disease, as the data shows that Vascepa, a drug derived from omega-3 oils that is commonly used to treat hypertriglyceridemia, a disease that causes elevated fat levels in blood, also reduces the progression of heart disease.